Key Points
- CEO Marvin Slosman bought 21,000 shares of InspireMD at an average price of $1.20, a transaction worth $25,200, increasing his ownership by 0.59%.
- InspireMD shares last traded at $1.17, near their 52-week low of $1.02, with a market cap of $54.8 million and stock performance below both the 50-day and 200-day moving averages.
- Analysts remain generally upbeat on the stock, with a consensus Buy rating and an average price target of $4.50, while the company continues to commercialize its CGuard embolic prevention system.
InspireMD, Inc. (NYSE:NSPR - Get Free Report) CEO Marvin Slosman purchased 21,000 shares of the business's stock in a transaction on Tuesday, May 12th. The stock was purchased at an average price of $1.20 per share, with a total value of $25,200.00. Following the purchase, the chief executive officer owned 3,556,658 shares of the company's stock, valued at approximately $4,267,989.60. The trade was a 0.59% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
InspireMD Price Performance
Shares of NSPR stock opened at $1.17 on Thursday. The stock has a market cap of $54.80 million, a P/E ratio of -1.56 and a beta of 0.82. The company has a fifty day moving average price of $1.46 and a two-hundred day moving average price of $1.72. InspireMD, Inc. has a one year low of $1.02 and a one year high of $2.93.
Hedge Funds Weigh In On InspireMD
A number of hedge funds have recently bought and sold shares of NSPR. XTX Topco Ltd bought a new position in InspireMD during the fourth quarter worth about $30,000. Virtu Financial LLC bought a new position in InspireMD during the fourth quarter worth about $31,000. Creative Planning bought a new position in InspireMD during the second quarter worth about $44,000. Legato Capital Management LLC bought a new position in InspireMD during the fourth quarter worth about $48,000. Finally, Uniting Wealth Partners LLC bought a new position in InspireMD during the third quarter worth about $51,000. 44.78% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on NSPR. Maxim Group began coverage on shares of InspireMD in a research report on Monday, February 2nd. They issued a "buy" rating and a $6.00 price objective on the stock. Loop Capital set a $5.00 price target on shares of InspireMD in a research report on Tuesday, February 24th. Piper Sandler reaffirmed an "overweight" rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Finally, Lake Street Capital set a $4.00 price target on shares of InspireMD in a research report on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, InspireMD presently has a consensus rating of "Buy" and a consensus target price of $4.50.
Check Out Our Latest Stock Analysis on InspireMD
InspireMD Company Profile
(
Get Free Report)
InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company's core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.
The company's flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
